Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2853)
All Articles published online
|
Mar 1, 2004 (publication date) through Nov 30, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Guo CY, Wu YB, Liu HL, Wu JY, Zhong MZ. Clinical evaluation of four one-week triple therapy regimens in eradicating Helicobacter pylori infection. World J Gastroenterol 2004; 10(5): 747-749 [PMID: 14991953 DOI: 10.3748/wjg.v10.i5.747] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v10/i5/747.htm |
| Number | Citing Articles |
| 1 |
Ying-Qun Zhou, Ling Xu, Bing-Fang Wang, Xiao-Ming Fan, Jian-Ye Wu, Chun-Yan Wang, Chuan-Yong Guo, Xuan-Fu Xu. Modified Sequential Therapy Regimen versus Conventional Triple Therapy forHelicobacter pyloriEradication in Duodenal Ulcer Patients in China: A Multicenter Clinical Comparative Study. Gastroenterology Research and Practice 2012; 2012: 1 doi: 10.1155/2012/405425
|
| 2 |
Samson Cantu, Mark A. Gilger. Feigin and Cherry's Textbook of Pediatric Infectious Diseases. 2009; : 1765 doi: 10.1016/B978-1-4160-4044-6.50152-7
|
| 3 |
Tao Wu, Lichen Wang, Meiliang Gong, Yunjuan Lin, Yaping Xu, Ling Ye, Xiang Yu, Jing Liu, Jianwei Liu, Shuli He, Hao Zeng, Gangshi Wang. Synergistic effects of nanoparticle heating and amoxicillin on H. pylori inhibition. Journal of Magnetism and Magnetic Materials 2019; 485: 95 doi: 10.1016/j.jmmm.2019.04.076
|
| 4 |
Faezeh Kiani, Sara Khademolhosseini, Mobina Fathi, Arian Tavasol, Jasem Mohammadi, Majid Dousti, Jalal Eshagh Hoseini. Standard Triple Therapy as a Remedy for Treatment of Helicobacter pylori
Infection: A Systematic Review and Meta-analysis of Randomized Clinical
Trials. Current Reviews in Clinical and Experimental Pharmacology 2023; 18(2): 167 doi: 10.2174/2772432817666220317152544
|
| 5 |
György M Buzás, Jolán Józan. Nitrofuran‐based regimens for the eradication of Helicobacter pylori infection. Journal of Gastroenterology and Hepatology 2007; 22(10): 1571 doi: 10.1111/j.1440-1746.2007.05082.x
|
| 6 |
Chao-ran Ji, Jing Liu, Yue-yue Li, Chuan-guo Guo, Jun-yan Qu, Yan Zhang, Xiuli Zuo. Safety of furazolidone-containing regimen in Helicobacter pylori infection: a systematic review and meta-analysis. BMJ Open 2020; 10(10): e037375 doi: 10.1136/bmjopen-2020-037375
|
| 7 |
Faezeh Kiani, Sara Khademolhosseini, Jasem Mohammadi, Arian Tavasol, Ramtin Hajibeygi, Mobina Fathi, Majid Dousti. Novel Information Regarding the Treatment of Helicobacter pylori Infection:
A Systematic Review and Meta-analysis of Randomized Clinical Trials. Current Reviews in Clinical and Experimental Pharmacology 2024; 19(2): 184 doi: 10.2174/2772432818666230120111237
|
| 8 |
Ben Wang, Zhi-Fa Lv, You-Hua Wang, Hui Wang, Xiao-Qun Liu, Yong Xie, Xiao-Jiang Zhou. Standard triple therapy for <italic>Helicobacter pylori</italic> infection in China: A meta-analysis. World Journal of Gastroenterology 2014; 20(40): 14973-14985 doi: 10.3748/wjg.v20.i40.14973
|
| 9 |
Quan Zhou, Ling-Ling Zhu, Xiao-Feng Yan, Wen-Sheng Pan, Su Zeng. Drug utilization of clarithromycin for gastrointestinal disease treatment. World Journal of Gastroenterology 2008; 14(39): 6065-6071 doi: 10.3748/wjg.14.6065
|
| 10 |
Ying Ying Han, Ji Yan Li, Jia Lun Guan, Mei Liu, Pei Yuan Li. Application of furazolidone in Helicobacter pylori infection eradication. Journal of Digestive Diseases 2024; 25(3): 148 doi: 10.1111/1751-2980.13265
|
| 11 |
Naoki Chiba. Evidence‐Based Gastroenterology and Hepatology. 2010; : 102 doi: 10.1002/9781444314403.ch6
|
| 12 |
Eva C. Arrua, Sofía V. Sanchez, Valeria Trincado, Antonio Hidalgo, Andrew F.G. Quest, Javier O. Morales. Experimental design and optimization of a novel dual-release drug delivery system with therapeutic potential against infection with Helicobacter pylori. Colloids and Surfaces B: Biointerfaces 2022; 213: 112403 doi: 10.1016/j.colsurfb.2022.112403
|
| 13 |
Yong Xie, Zhenyu Zhang, Junbo Hong, Wenzhong Liu, Hong Lu, Yiqi Du, Weihong Wang, Jianming Xu, Xuehong Wang, Lijuan Huo, Guiying Zhang, Chunhui Lan, Xiaoyan Li, Yanqing Li, Hong Wang, Guoxin Zhang, Yin Zhu, Xu Shu, Ye Chen, Jiangbin Wang, Nonghua Lu. Furazolidone‐containing triple and quadruple eradication therapy for initial treatment for Helicobacter pylori infection: A multicenter randomized controlled trial in China. Helicobacter 2018; 23(5) doi: 10.1111/hel.12496
|
| 14 |
Liya Zhuge, Youhua Wang, Shuang Wu, Ru‐Lin Zhao, Zhen Li, Yong Xie. Furazolidone treatment for Helicobacter Pylori infection: A systematic review and meta‐analysis. Helicobacter 2018; 23(2) doi: 10.1111/hel.12468
|
| 15 |
A. A. NIJEVITCH, P. L. SHCHERBAKOV, V. U. SATAEV, R. SH. KHASANOV, R. AL KHASHASH, M. M. TUYGUNOV. Helicobacter pylori eradication in childhood after failure of initial treatment: advantage of quadruple therapy with nifuratel to furazolidone. Alimentary Pharmacology & Therapeutics 2005; 22(9): 881 doi: 10.1111/j.1365-2036.2005.02656.x
|
| 16 |
Fernando M Silva, Jaime N Eisig, Ana Cristina S Teixeira, Ricardo C Barbuti, Tomás Navarro-Rodriguez, Rejane Mattar. Short-term triple therapy with azithromycin for Helicobacter pylori eradication: Low cost, high compliance, but low efficacy. BMC Gastroenterology 2008; 8(1) doi: 10.1186/1471-230X-8-20
|
| 17 |
Min Luo, Yi-Yang Jia, Zi-Wei Jing, Chen Li, Si-Yuan Zhou, Qi-Bing Mei, Bang-Le Zhang. Construction and optimization of pH-sensitive nanoparticle delivery system containing PLGA and UCCs-2 for targeted treatment of Helicobacter pylori. Colloids and Surfaces B: Biointerfaces 2018; 164: 11 doi: 10.1016/j.colsurfb.2018.01.008
|
| 18 |
Angelo Zullo, Cesare Hassan, Salvatore MA Campo, Sergio Morini. Evolving therapy for Helicobacter pylori infection. Expert Opinion on Therapeutic Patents 2004; 14(10): 1453 doi: 10.1517/13543776.14.10.1453
|
| 19 |
Yu-Hsin Lin, Jui-Hsiang Lin, Shen-Chieh Chou, Shu-Jen Chang, Chun-Chia Chung, Yueh-Sheng Chen, Chiung-Hung Chang.
Berberine-Loaded Targeted Nanoparticles as Specific
Helicobacter Pylori
Eradication Therapy:
In Vitro
and
In Vivo
Study
. Nanomedicine 2015; 10(1): 57 doi: 10.2217/nnm.14.76
|
| 20 |
Conghua Song, Xing Qian, Yin Zhu, Xu Shu, Yanping Song, Zhijuan Xiong, Jianfang Ye, Tao Yu, Ling Ding, Hui Wang, Nonghua Lu, Yong Xie. Effectiveness and safety of furazolidone‐containing quadruple regimens in patients with Helicobacter pylori infection in real‐world practice. Helicobacter 2019; 24(4) doi: 10.1111/hel.12591
|
| 21 |
Karin Van Amsterdam, Arnoud H. M. Van Vliet, Johannes G. Kusters, Arie Van Der Ende. Of microbe and man: determinants ofHelicobacter pylori-related diseases. FEMS Microbiology Reviews 2006; 30(1): 131 doi: 10.1111/j.1574-6976.2005.00006.x
|
| 22 |
Johannes G. Kusters, Arnoud H. M. van Vliet, Ernst J. Kuipers. Pathogenesis ofHelicobacter pyloriInfection. Clinical Microbiology Reviews 2006; 19(3): 449 doi: 10.1128/CMR.00054-05
|
| 23 |
Jiang Lin, Wei-Wen Huang. A systematic review of treating <italic>Helicobacter pylori</italic> infection with Traditional Chinese Medicine. World Journal of Gastroenterology 2009; 15(37): 4715-4719 doi: 10.3748/wjg.15.4715
|
| 24 |
S. Turi, D. Schilling, J. F. Riemann. Eradikation und chronische S�ureblockade. Der Internist 2004; 45(11): 1305 doi: 10.1007/s00108-004-1237-0
|